Role of Th1 and Th2 cytokines in BCG-induced IFN-γ production: cytokine promotion and simulation of BCG effect

Alexandroff, 1999, BCG immunotherapy of bladder cancer: 20 years on, Lancet, 353, 1689, 10.1016/S0140-6736(98)07422-4 O'Donnell, 1995, Bacillus Calmette-Guérin immunotherapy for superficial bladder cancer: new prospects for an old warhorse, Surg Oncol Clin North Am, 4, 189, 10.1016/S1055-3207(18)30447-2 O'Donnell, 2001, Use of intravesical BCG in treatment of superficial bladder cancer, 225 Bohle, 1990, Elevations of cytokines interleukin-1, interleukin-2 and tumor necrosis factor in the urine of patients after intravesical bacillus Calmette-Guérin immunotherapy, J Urol, 144, 59, 10.1016/S0022-5347(17)39366-7 de Reijke, 1996, Urinary cytokines during intravesical bacillus Calmette-Guérin therapy for superficial bladder cancer: processing, stability and prognostic value, J Urol, 155, 477, 10.1016/S0022-5347(01)66424-3 Esuvaranathan, 1995, Interleukin-6 production by bladder tumors is upregulated by BCG immunotherapy, J Urol, 154, 572, 10.1016/S0022-5347(01)67113-1 Prescott, 1990, Radio-immunoassay detection of interferon-gamma in urine after intravesical Evans BCG therapy, J Urol, 144, 1248, 10.1016/S0022-5347(17)39713-6 Thalmann, 2000, Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guérin, J Urol, 164, 2129, 10.1016/S0022-5347(05)66983-2 Alexandroff, 1996, Production of IL-5, a classical TH2 cytokine, following bacillus Calmette-Guérin immunotherapy of bladder cancer, Int J Oncol, 9, 179 Huygen, 1992, Spleen cell cytokine secretion in Mycobacterium bovis BCG-infected mice, Infect Immun, 60, 2880, 10.1128/IAI.60.7.2880-2886.1992 Pavlovich, 2000, BCG-induced urinary cytokines inhibit microvascular endothelial cell proliferation, J Urol, 163, 2014, 10.1016/S0022-5347(05)67620-3 Poppas, 1998, Intravesical BCG induces the anti-angiogenic chemokine IP-10, Urology, 52, 268, 10.1016/S0090-4295(98)00188-5 Weiss, 1999, Phase I trial of the intravesical administration of recombinant human interleukin-12 (rhIL-12) for superficial transitional cell bladder carcinoma (STCC), Am Soc Clin Oncol, 18, 334a O'Donnell, 1996, Maturation of the cytokine immune response to BCG in the bladder: implications for treatment schedules, J Urol, 155, 1030A Riemensberger, 2002, IFN-gamma and IL-12 but not IL-10 are required for local tumour surveillance in a syngeneic model of orthotopic bladder cancer, Clin Exp Immunol, 127, 20, 10.1046/j.1365-2249.2002.01734.x McAveney, 1994, Induction of TH1- and TH2-associated cytokine mRNA in mouse bladder following intravesical growth of the murine bladder tumor MB49 and BCG immunotherapy, Cancer Immunol Immunother, 39, 401, 10.1007/BF01534428 Ratliff, 1993, T-cell subsets required for intravesical BCG immunotherapy for bladder cancer, J Urol, 150, 1018, 10.1016/S0022-5347(17)35678-1 Ratliff, 1992, Role of the immune response in BCG for bladder cancer, Eur Urol, 21, 17, 10.1159/000474916 Lamm, 1992, Long-term results of intravesical therapy for superficial bladder cancer, Urol Clin North Am, 19, 573, 10.1016/S0094-0143(21)00424-9 Dejager, 1991, Long-term complete remission in bladder carcinoma in situ with intravesical Tice bacillus Calmette-Guérin, Urology, 38, 507, 10.1016/0090-4295(91)80166-5 Herr, 1986, Long-term effect of intravesical bacillus Calmette-Guérin on flat carcinoma in situ of the bladder, J Urol, 135, 265, 10.1016/S0022-5347(17)45604-7 Steg, 1992, BCG therapy in superficial bladder tumours—complications and precautions, Eur Urol, 21, 35, 10.1159/000474920 Lamm, 1992, Incidence and treatment of complications of bacillus Calmette-Guérin intravesical therapy in superficial bladder cancer, J Urol, 147, 596, 10.1016/S0022-5347(17)37316-0 Naitoh, 1999, Interferon alpha for the treatment of superficial bladder cancer, Adv Exp Med Biol, 462, 371, 10.1007/978-1-4615-4737-2_29 Luo, 1999, IFN-α 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette-Guérin immunotherapy, J Immunol, 162, 2399, 10.4049/jimmunol.162.4.2399 Clinton, 2000, Interleukin-12: opportunities for the treatment of bladder cancer, Urol Clin North Am, 27, 147, 10.1016/S0094-0143(05)70242-1 Bercovich, 1995, BCG vs. BCG plus recombinant alpha-interferon 2b in superficial tumors of the bladder, Arch Ital Urol Androl, 67, 257 Stricker, 1996, Bacillus Calmette-Guérin plus intravesical interferon alpha-2b in patients with superficial bladder cancer, Urology, 48, 957, 10.1016/S0090-4295(96)00375-5 Gomella, 1993, Treatment of transitional cell carcinoma of the bladder with intravesical interleukin-2: a pilot study, Cancer Biother, 8, 223, 10.1089/cbr.1993.8.223 Glazier, 1995, Intravesical recombinant tumor necrosis factor in the treatment of superficial bladder cancer: an eastern cooperative oncology group study, J Urol, 154, 66, 10.1016/S0022-5347(01)67228-8 Saint, 2002, Prognostic value of a T helper 1 urinary cytokine response after intravesical bacillus Calmette-Guerin treatment for superficial bladder cancer, J Urol, 167, 364, 10.1016/S0022-5347(05)65469-9 Fujimoto, 1996, Bacillus Calmette-Guérin plus interleukin-2 and/or granulocyte/macrophage-colony-stimulating factor enhances immunocompetent cell production of interferon-γ, which inhibits B16F10 melanoma cell growth in vitro, Cancer Immunol Immunother, 42, 280, 10.1007/s002620050283 O'Donnell, 1999, Role of IL-12 in the induction and potentiation of IFN-γ in response to bacillus Calmette-Guérin, J Immunol, 163, 4246, 10.4049/jimmunol.163.8.4246 Seder, 1993, Interleukin 12 acts directly on CD4+ T cells to enhance priming for interferon-γ production and diminishes interleukin 4 inhibition of such priming, Proc Natl Acad Sci USA, 90, 10188, 10.1073/pnas.90.21.10188 Scharton, 1993, Natural killer cells are a source of interferon gamma that drives differentiation of CD4+ T cell subsets and induces early resistance to Leishmania major in mice, J Exp Med, 178, 567, 10.1084/jem.178.2.567 Chan, 1991, Induction of IFN-γ production by NK cell stimulatory factor (NKSF): characterization of the responder cells and synergy with other inducers, J Exp Med, 173, 869, 10.1084/jem.173.4.869 Kobayashi, 1989, Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes, J Exp Med, 170, 827, 10.1084/jem.170.3.827 Trinchieri, 1995, Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity, Ann Rev Immunol, 13, 251, 10.1146/annurev.iy.13.040195.001343 Manetti, 1993, Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells, J Exp Med, 177, 1199, 10.1084/jem.177.4.1199 Fearon, 1996, The instructive role of innate immunity in the acquired immune response, Science, 27, 50, 10.1126/science.272.5258.50 Kishimoto, 1995, Interleukin-6 family of cytokines and gp130, Blood, 86, 1243, 10.1182/blood.V86.4.1243.bloodjournal8641243 Kawano, 1995, Regulation of human IgG subclass production by cytokines: human IgG subclass production enhanced differentially by interleukin-6, Immunology, 84, 278 Ramsay, 1994, The role of interleukin-6 in mucosal IgA antibody responses in vivo, Science, 264, 561, 10.1126/science.8160012 Taga, 1987, Receptors for B cell stimulatory factor 2. Quantitation, specificity, distribution, and regulation of their expression, J Exp Med, 166, 967, 10.1084/jem.166.4.967 Stavropoulos, 2000, Intravesical instillations of interferon gamma in the prophylaxis of high risk superficial bladder cancer, Scand J Urol Nephrol, 36, 218, 10.1080/003655902320131910 Stover, 1991, New use of BCG for recombinant vaccines, Nature, 351, 456, 10.1038/351456a0